Astonea Labs H1FY27: consol PAT +149% YoY to ₹4.74 Cr, margins expand, revenue +45%
PAT +148.9% YoY · revenue +44.6% · margins expanding
₹95.86 Cr
+44.6% YoY
₹4.74 Cr
+148.9% YoY
4.93%
+2.8pp YoY
₹4.59
Astonea Labs' H1 FY27 (half year ended 30 Sept 2026) consolidated revenue rose 44.6% YoY to ₹95.86 Cr (H1 FY26: ₹66.29 Cr) and consolidated PAT rose ~149% YoY to ₹4.74 Cr (H1 FY26: ₹1.90 Cr). The print carries a ₹46.16 Lakh exceptional item — the uninsured portion of inventory destroyed in an April 27, 2026 factory fire — so reported PAT growth actually understates the underlying trend: adjusting for that one-off, PAT growth is ~173% YoY. Margins expanded alongside the growth: consolidated net profit margin moved to ~4.9% from ~2.9%, and EBITDA margin (profit before exceptional items/tax plus finance costs and depreciation, net of other income) widened to ~13.4% from ~8.1% a year earlier, pointing to operating leverage rather than one-off gains driving the improvement.
Q2 FY-2027 vs prior quarters
There is no analyst coverage of the stock (zero analysts tracked per Simply Wall St), so a street-estimate comparison isn't possible. Against management's own FY27 guidance of ₹215-230 Cr revenue (45-55% YoY growth, disclosed in its FY26 results commentary), H1's 44.6% YoY growth sits right at the floor of that range — on track, but H2 revenue would need to step up to roughly ₹119-134 Cr from H1's ₹95.86 Cr to clear the guided band, a meaningfully higher run-rate than H1 delivered. Management had separately flagged FY26 profit pressure from 'strategic investments in distribution, branding and regulatory infrastructure' with margin recovery expected in FY27; this half's margin expansion is consistent with that framing, though the fire loss is a fresh, unguided drag the company will need to absorb. The same board meeting approved a ₹12 Cr annual related-party transaction ceiling with newly incorporated Longevity Science Pvt Ltd, in which Astonea is subscribing to a 51% stake — a forward expansion step that has no P&L impact yet since incorporation (Oct 8, 2026) falls after the reporting half.
The stock went into the print at ₹350, up 11.6% over the past month of trading.
For context: this is the highest quarterly PAT in the last 4 quarters on our records.
What the summary numbers don't show
First half-year results prepared under voluntarily adopted Ind AS (effective 01-Apr-2026); FY26 comparatives restated
No analyst coverage exists for the stock (0 analysts per Simply Wall St) — filing is half-yearly (BSE SME cadence), so no standalone quarterly (Q2-only) figures or QoQ comparison are available
W1
H2 FY27 revenue run-rate: needs to rise to roughly ₹119-134 Cr from H1's ₹95.86 Cr to hit management's own ₹215-230 Cr FY27 guidance
W2
Final insurance claim settlement and total P&L recognition for the April 2026 factory fire, currently disclosed at ₹5.50 Cr pending assessment
W3
Consolidation impact once Longevity Science Pvt Ltd (51% stake) formally becomes a subsidiary in H2 FY27, and resolution of the ₹84.99 Lakh reversed input tax credit under review
This is a half-yearly filing (half year ended 30.09.2026), not an isolated Q2 — the company (BSE SME scrip 544409, first Ind AS period from 01.04.2026) files H1/full-year, so no Q1-only or Q2-only column exists and QoQ is not derivable; our DB 'year-ago quarterly' context (rev ₹66.291 Cr matches H1 FY26 almost exactly, but PAT ₹1.418 Cr vs the filing's own reviewed H1 FY26 comparative of ₹1.904 Cr) appears to be this same H1 FY26 period under a different/earlier basis — YoY below uses the PDF's own comparative column. Current-half PBT/PAT carries a ₹46.16 Lakh exceptional item (uninsured inventory loss from an Apr-27-2026 factory fire); a broader ₹5.50 Cr fire-related amount is separately disclosed by auditors pending final insurance assessment. Consolidated figures include an equity-accounted associate (Damaira Pharmaceuticals) prepared under IGAAP; the new subsidiary Longevity Science Pvt Ltd (incorporated 08-Oct-2026) is a non-adjusting post-period event, not consolidated this half. ₹84.99 Lakh of reversed input tax credit is under reconciliation, outcome unknown.